BRAF and melanoma: More recent data support the activity of cobimetinib plus vemurafenib in an agnostic fashion showing promising ORR (57%) in solid tumours (n = 31) with BRAF V600E mutations; however EMA marketing authorisation is currently available only for melanoma.51